SCHEMBL5557692

SCHEMBL5557692

O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCC2(CC1)C(=O)N(c1cc(Cl)ncn1)CN2c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DDR1 Q08345 11/20 0.55
CYP3A4 P08684 4/20 0.52
TSHR P16473 3/20 0.52
USP2 O75604 3/20 0.51
HSD17B10 Q99714 2/20 0.51
OPRD1 P41143 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 1/20 0.47
CYP2D6 P10635 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
HIF1A Q16665 1/20 0.47
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5557809 0.90 DDR1 (0.48) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5558353 0.86 DDR1 (0.56) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5557616 0.86 DDR1 (0.58) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5558472 0.86 DDR1 (0.58) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5557608 0.85 DDR1 (0.55) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5559756 0.84 DDR1 (0.57) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5558411 0.84 DDR1 (0.58) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5557560 0.84 DDR1 (0.57) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5559704 0.84 DDR1 (0.57) DDR1CYP3A4TSHRUSP2HSD17B10
SCHEMBL5553201 0.83 DDR1 (0.57) DDR1CYP3A4TSHRUSP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US claimed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US claimed
EP-1292596-B1 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor TACR1, TACR2, NPR1 DDR1 1165/4885CYP3A4 3223/4885TSHR 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.